سعر سكيزونكس 25مجم 50 اقراص 2022

Schizonex 25 mg 50 tablets: clozapine 25 mg tablets, pack of 50, by Pharco (Egypt); an atypical antipsychotic used for treatment-resistant schizophrenia.

• Treatment-resistant schizophrenia (patients who have failed to respond adequately to standard antipsychotic treatment).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder judged to be at chronic risk.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (5% or more): sedation, dizziness/vertigo, headache, tremor, tachycardia, hypotension, syncope, hypersalivation, sweating, dry mouth, visual disturbances, constipation, nausea and fever.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known serious hypersensitivity to clozapine or any other component of the product.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: severe neutropenia, which can lead to serious and fatal infections. Do not start if baseline ANC is below 1500/microliter (below 1000/microliter in benign ethnic neutropenia).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: orthostatic hypotension, bradycardia and syncope, highest during initial titration and on restarting after even a brief interruption; start at 12.5 mg, titrate slowly and use divided doses.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: dose-related seizures; use caution in patients with a seizure history or risk factors and caution about activities where sudden loss of consciousness is dangerous.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin)Reduce the clozapine dose to one-third.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducersConcomitant use is not recommended; if necessary, the clozapine dose may need to be increased with monitoring for decreased effectiveness.DailyMed (U.S. National Library of Medicine)
• CYP2D6 or CYP3A4 inhibitors; moderate or weak CYP1A2 inhibitorsMonitor for adverse reactions and consider reducing the clozapine dose if necessary.DailyMed (U.S. National Library of Medicine)

• Published epidemiologic data over decades of use have not established a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; there are risks with untreated schizophrenia.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Clozapine is present in human milk; sedation and agranulocytosis have been reported in exposed infants. Monitor breastfed infants for excess sedation and neutropenia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Clozapine: Multi-receptor antagonist including dopamine D2 and serotonin 5-HT2A; unique efficacy in treatment-resistant schizophrenia with agranulocytosis risk.